RxDoctor Payments Data

Sujatha Rajagopalan, MD

Internal Medicine · San Ramon, CANPI 1679558373

Payments from drug & device makers

$748in general payments, 2019–2025

Across 30 payments — averaging $24.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$141
  • AbbVie$136
  • Amgen$123
  • Pfizer$120
  • Exact Sciences$107
  • GSK$66
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$748100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$748 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$116,675
Medicare patients
487
Services billed
3,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$65,927
JardianceEmpagliflozin20$31,786
JanuviaSitagliptin Phosphate27$31,603
OzempicSemaglutide20$20,342
JanumetSitagliptin Phos/Metformin Hcl13$13,831
SynthroidLevothyroxine Sodium80$6,358
Atorvastatin Calcium631$5,527
Levothyroxine Sodium408$5,160
Valsartan84$4,201
Rosuvastatin Calcium233$3,530
Gabapentin144$2,546
Amlodipine Besylate402$2,257
Metoprolol Succinate134$2,202
Celecoxib11$2,176
Fluticasone Propionate77$1,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$120$67,35663 claims
Novo NordiskOzempic$18$20,34220 claims
AbbVieSynthroid$136$6,35880 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Ramon

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →